A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

December 1, 2025

Conditions
Lupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Interventions
DRUG

Placebo

Placebo (intravenous infusion)

DRUG

PF-06823859

PF-06823859 (intravenous infusion)

Trial Locations (19)

16121

Ionos Dragoumi 5 Kaisariani, Kaisarianí

28041

Hospital Universitario 12 de Octubre, Madrid

30322

Emory University, Atlanta

35233

The Kirklin Clinic of UAB Hospital, Birmingham

University of Alabama at Birmingham - School of Medicine, Birmingham

University of Alabama at Birmingham, Department of Dermatology, Birmingham

35249

The University of Alabama at Birmingham, Birmingham

41013

Hospital Universitario Virgen Del Rocio, Seville

44195

Cleveland Clinic Foundation, Cleveland

66160

The University of Kansas Hospital, Kansas City

University of Kansas Medical Center, Kansas City

85054

Mayo Clinic Hospital, Phoenix

85259

Mayo Clinic in Arizona - Scottsdale, Scottsdale

90045

Dermatology Research Associates, Los Angeles

N6H 5L5

DermEffects, London

M4W 2N4

Dermatology on Bloor - Research Toronto, Toronto

L1P 1Y5

Oshawa Clinic Dermatology Trials, Whitby

124 62

Attikon General University Hospital, Chaïdári

161 21

Dermatological and Venereological Hospital Andreas Syggros, Athens

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05879718 - A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. | Biotech Hunter | Biotech Hunter